Downloaded 15 times
Uploaded byFight Colorectal Cancer
Oct 2015 Webinar: Dr. Lieu, Precision Medicine
The webinar focuses on the role of research advocates in precision medicine and immunotherapy for colorectal cancer, featuring Dr. Christopher Lieu from the University of Colorado. It highlights the aims of the Research Advocacy Training and Support program to enhance advocates' participation in the research process and discusses key topics such as biomarkers and immunotherapy treatments. The session also addresses the importance of patient perspectives in research and encourages audience engagement through a Q&A segment.
More Related Content
Similar to Oct 2015 Webinar: Dr. Lieu, Precision Medicine
![Molecular target therapy_in_colorectal_cancer[1]](https://cdn.slidesharecdn.com/ss_thumbnails/moleculartargettherapyincolorectalcancer1-171117132543-thumbnail.jpg?width=640&height=640&fit=bounds)
More from Fight Colorectal Cancer
Oct 2015 Webinar: Dr. Lieu, Precision Medicine
- 1. Precision Medicine and Immunotherapy ResearchAdvocacy Training and Support Program Our webinar will begin shortly. WELCOME!
- 2. • Speaker(s): Dr.Christopher Lieu, MD University of Colorado Gastrointestinal Malignancies Program • Archived Webinars: FightColorectalCancer.org/Webinars • AFTER THE WEBINAR: Expect an email with links to the recording. • Ask a question in the panel on the RIGHT SIDE of your screen • Follow along via Twitter – use the hashtag #CRCWebinar Today’s Webinar:
- 3. What is aRESEARCH ADVOCATE? A research advocate brings a patient viewpoint to the research process and communicates a collective patient perspective Fight CRC’s Research Advocacy Training and Support (RATS) Program: • Goal is to improve the ability of research advocates to effectively participate in the research process. • In person meetings, online trainings, and webinars. • Continued education and ongoing training and support Brought to you by RATS:
- 4.
- 5. Disclaimer : The information andservices provided by Fight Colorectal Cancer are for general informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnoses or treatment. If you are ill, or suspect that you are ill, see a doctor immediately. In an emergency, call 911 or go to the nearest emergency room. Fight Colorectal Cancer never recommends or endorses any specific physicians, products or treatments for any condition.
- 6. Speaker: Chris Lieu,M.D. Dr. Lieu is one of our hosts for the research advocacy training at the University of Colorado. Dr. Lieu joined the University of Colorado School of Medicine faculty as an Assistant Professor in July 2011. He trained in internal medicine at the University of Colorado, where he also served as a Chief Medical Resident. He completed his fellowship training in medical oncology at the University of Texas MD Anderson Cancer Center and served as the Chief Medical Oncology Fellow in 2010.
- 7. Precision Medicine andImmunotherapy Research Advocacy Training and Support Christopher Lieu, MD University of Colorado Gastrointestinal Malignancies Program October 22, 2015 Christopher Lieu, MD University of Colorado Gastrointestinal Malignancies Program Christopher Lieu, MD University of Colorado Gastrointestinal Malignancies Program
- 8. Agenda • Know YourBiomarker • Science Behind Biomarkers • Immunotherapy • Questions
- 16. The Science BehindBiomarkers Show me the Data!
- 17. RAS Mutations Predict(Lack of) Benefit to EGFR Therapy Refractory CRC R Cetuximab alone Best supportive care Karapetis et al. NEJM 2008, 359 (17): 1757
- 18. BRAF Mutant ColonCancer: Atypical Location of Metastases and Poor Survival Tran, Kopetz, et al, Cancer ‘11 0% 50% 100% 150% 200% 250% BRAF wild type P<0.05 P<0.05 P<0.05 P<0.05 Increasedincidence comparedtoBRAFwildtype Hazard Ratio of 10.6 for OS Less than 1 year OS
- 19. BRAF inhibition inMelanoma
- 20. BRAF Inhibition inMelanoma Wagle et al. J Clin Oncol. 2011.
- 21.
- 22. The Importance ofthe PD-1/PD-L1 Pathway • Inhibiting PD-L1/PD-1 and PD- L1/B7.1 interactions can restore antitumor T-cell activity and enhance T-cell priming • Antibodies that bind to PD-1 and PD- L1 are currently in development • Nivolumab and pembrolizumab are currently FDA-approved 1. Akbari. Mucosal Immunol. 2010; 2. Matsumoto. Biochem Biophys Res Commun. 2008.
- 23.
- 24.
- 25.
- 26. Summary • Biomarker testingis becoming more common, especially in clinical trials – Testing is usually performed by biopsy, but new technologies are emerging (e.g. liquid biopsy) • We are limited by what we don’t know about cancer biology – Biomarkers aren’t perfect • Immunotherapies are emerging as effective treatment options – Currently, they do not work for all tumors
- 27. Question & Answer: SNAPA #STRONGARMSELFIE Bayer HealthCare will donate $1 for every photo posted (up to $25,000). Flex a “strong arm” & post it to Twitter or Instagram! (Use the hashtag!)